Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 3/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.95 |
| ▸ | MEN1 | O00255 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.95 |
| ▸ | POLB | P06746 | 1/20 | 0.95 |
| ▸ | GAA | P10253 | 1/20 | 0.95 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.95 |
| ▸ | HPGD | P15428 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.95 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | DHFR | P00374 | 7/20 | 0.64 |
| ▸ | GART | P22102 | 2/20 | 0.64 |
| ▸ | ATIC | P31939 | 2/20 | 0.64 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.55 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Folic Acid SCHEMBL3517969 | 0.98 | TYMS (0.91) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL29624885 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL3877 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL29349485 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL403054 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL16492117 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL29388311 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL332170 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL248712 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL29441959 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142109-A1 | ANTIFOLATE COMBINATIONS | CHELSEA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8658652-B2 | Antifolate combinations | CHELSEA THERAPEUTICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8530653-B2 | Enzyme inhibiting compounds | CHELSEA THERAPEUTICS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120142692-A1 | ANTIFOLATE COMBINATIONS | CHELSEA THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20110237609-A1 | ANTIFOLATE COMPOSITIONS | CHELSEA THERAPEUTICS, INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110152276-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS ANTIFOLATES | Chelsea Thereapeutics, Inc. | 2011-06-23 | — | — | US | disclosed |
| US-7951812-B2 | For abnormal cell proliferation, inflammatory diseases, asthma, and arthritis; (S)-N-{4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-4-methylene-L-glutamic acid disodium salt (CHL1007) | CHELSEA THERAPEUTICS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110124650-A1 | STABLE CRYSTALLINE SALTS OF ANTIFOLATE COMPOUNDS | CHELSEA THERAPEUTICS, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110112126-A1 | ENZYME INHIBITING COMPOUNDS | CHELSEA THERAPEUTICS, INC. | 2011-05-12 | — | — | US | disclosed |
| EP-2300441-A1 | CRYSTALLINE SALT FORMS OF ANTIFOLATE COMPOUNDS AND METHODS OF MANUFACTURING THEREOF | Chelsea Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009126639-A1 | CRYSTALLINE SALT FORMS OF ANTIFOLATE COMPOUNDS AND METHODS OF MANUFACTURING THEREOF | CHELSEA THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090253720-A1 | ANTIFOLATE COMPOSITIONS | CHELSEA THERAPEUTICS, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090253719-A1 | CRYSTALLINE SALT FORMS OF ANTIFOLATE COMPOUNDS AND METHODS OF MANUFACTURING THEREOF | CHELSEA THERAPEUTICS, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20080214585-A1 | NEW CLASSICAL ANTIFOLATES | CHELSEA THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152276-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS ANTIFOLATES | CCR9, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNO | TYMS 154/4885KDM4E 1333/4885MEN1 4741/4885 |
| US-20140142109-A1 | ANTIFOLATE COMBINATIONS | DHFR, MTX1, MTHFD1 | TYMS 12/4885KDM4E 1152/4885MEN1 2252/4885 |
| US-20080214585-A1 | NEW CLASSICAL ANTIFOLATES | FFAR3, CCR9, NR1H3 | TYMS 1972/4885KDM4E 1415/4885MEN1 4098/4885 |
| US-20120142692-A1 | ANTIFOLATE COMBINATIONS | DHFR, MTX1, MTHFD1 | TYMS 12/4885KDM4E 1152/4885MEN1 2252/4885 |
| US-20090253720-A1 | ANTIFOLATE COMPOSITIONS | FDFT1, SLC19A1, FIBP | TYMS 389/4885KDM4E 3167/4885MEN1 4415/4885 |
| US-20110124650-A1 | STABLE CRYSTALLINE SALTS OF ANTIFOLATE COMPOUNDS | UACA, CCL11, ACKR3 | TYMS 79/4885KDM4E 3269/4885MEN1 3445/4885 |
| US-20110112126-A1 | ENZYME INHIBITING COMPOUNDS | FPGS, DHFR, TYMS | TYMS 3/4885KDM4E 635/4885MEN1 4057/4885 |
| US-20110237609-A1 | ANTIFOLATE COMPOSITIONS | DHFR, TYMS, MTHFD1 | TYMS 2/4885KDM4E 2238/4885MEN1 2985/4885 |
| US-20090253719-A1 | CRYSTALLINE SALT FORMS OF ANTIFOLATE COMPOUNDS AND METHODS OF MANUFACTURING THEREOF | SLC7A1, SLC10A1, SLC10A6 | TYMS 283/4885KDM4E 2180/4885MEN1 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.